SurModics Merger with GTCR LLC Clears Legal Hurdle

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.An announcement from SurModics ( (SRDX) ) is now available. On November 10, 2025, Surmodics, Inc. announced that the United States District Court for the Northern District of Illinois denied a request by the U.S. Federal Trade Commission and certain state regulators to issue a preliminary injunction that would have blocked the proposed acquisition of Surmodics by an affiliate of GTCR LLC. This decision marks a significant step towards completing the merger, which Surmodics believes will continue to deliver benefits for physicians, patients, and customers. The merger is still subject to a Temporary Restraining Order and other closing conditions, but the court’s ruling is seen as a positive development for the company’s future operations and strategic positioning. The most recent analyst rating on (SRDX) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on SurModics stock, see the SRDX Stock Forecast page. Spark’s Take on SRDX Stock According to Spark, TipRanks’ AI Analyst, SRDX is a Neutral. SurModics is currently facing substantial financial and market challenges. The most significant factors affecting the score are the company’s declining revenues and profitability issues, coupled with bearish technical indicators. The negative valuation metrics further underscore the need for strategic improvements to enhance financial health and investor confidence. To see Spark’s full report on SRDX stock, click here. More about SurModics Surmodics, Inc. is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company also develops and commercializes vascular intervention medical devices, leveraging its expertise in proprietary surface modification and drug-delivery coating technologies, along with device design, development, and manufacturing capabilities. Surmodics is headquartered in Eden Prairie, Minnesota, and focuses on improving the detection and treatment of disease. Average Trading Volume: 215,105 Technical Sentiment Signal: Buy Current Market Cap: $391M Find detailed analytics on SRDX stock on TipRanks’ Stock Analysis page.